News Lilly trumpets strong result for Jaypirca in CLL at EHA New data with Eli Lilly's Jaypirca at EHA 2026 has cemented its place as a second-line therapy for chronic lymphocytic leukaemia.
News Key pipeline drug for Lundbeck delivers in Cushing syndrome Lundbeck has reported positive trial results with Cushing's therapy asedebart, a key R&D prospect as it faces a patent cliff in the next few years.
News Data could move J&J's Talvey earlier in myeloma therapy Johnson & Johnson's Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026.
News Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest New data with Takeda's TYK2 inhibitor zasocitinib suggest it is significantly more effective than BMS's Sotyktu in the treatment of psoriasis.
News J&J adds rare disease wAIHA to Imaavy's potential uses Johnson & Johnson's 'Swiss army knife' drug Imaavy has shown efficacy in a pivotal trial involving patients with rare autoimmune disorder wAIHA.
News Novartis gets win for another Avidity muscular dystrophy AOC Novartis' $12bn takeover of Avidity could potentially give it the first therapy for genetic disorder facioscapulohumeral muscular dystrophy.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.